Epo receptors are not detectable in primary human tumor tissue samples

Area of Science:

• Oncology
• Cell Biology
• Hematology

Background:

• Erythropoietin (Epo) is a cytokine crucial for erythropoiesis, binding to the Epo receptor (EpoR) on erythroid progenitor cells.
• While EpoR is primarily in erythroid cells, low-level transcripts have been found in nonhematopoietic tissues and tumor cell lines.
• Conflicting data exists on EpoR protein expression in tumors due to the use of non-specific antibodies.

Purpose of the Study:

• To investigate the actual protein expression and functionality of the erythropoietin receptor (EpoR) in various human tumor cell lines and tissues.
• To clarify discrepancies in EpoR expression data caused by antibody specificity issues.

Main Methods:

• Utilized a specific monoclonal antibody (A82) to detect EpoR protein in normal human tissues, cancer tissues, and tumor cell lines (MCF-7, NCI-H838).
• Employed a polyclonal antibody (M-20) and assessed its specificity and potential for false-positive staining.
• Investigated EpoR functionality by examining rHuEpo-induced phosphorylation of downstream signaling molecules (AKT, STAT3, pS6RP, STAT5).

Main Results:

• The specific antibody A82 detected little to no EpoR protein in normal tissues, cancer tissues (breast, lung, colon, ovary, skin), and most tumor cell lines, including MCF-7.
• The polyclonal antibody M-20 showed false-positive staining and bound to a non-EpoR protein in MCF-7 cell lysates.
• While EpoR protein was detected in NCI-H838 cells, no functional response to rHuEpo (e.g., phosphorylation of signaling proteins) was observed.

Conclusions:

• The hypothesis that most tumors express high levels of functional EpoR protein is questionable based on these findings.
• The specificity of antibodies used in previous studies is critical for accurate EpoR detection and functional assessment.
• Further research is needed to definitively establish the role, if any, of EpoR in tumor biology.